The packing of acetylcholine into quanta at the frog neuromuscular junction is inhibited by increases in intracellular sodium

Calcitonin gene-related peptide acts presynaptically to increase quantal size and output at frog neuromuscular junctions

1. Calcitonin gene-related peptide (CGRP) is found in dense-cored vesicles in the motor nerve terminal. 2. Exogenous CGRP increased the size of the quanta. The increase in size reached a maximum after about 40 min. The lowest effective concentration of human CGRP (hCGRP) was 0.8 nM. The action of hCGRP was antagonized by (-)-vesamicol, a drug that blocks active acetylcholine (ACh) uptake into synaptic vesicles, so it appears that hCGRP increases size by adding more ACh to the quanta. The action of hCGRP was antagonized by drugs that block the activation of protein kinase A (PKA). (In other preparations CGRP also activates PKA.) 3. The hCGRP effect was not blocked by fragment 8-37, an antagonist of one class of CGRP receptor. 4. hCGRP increases evoked quantal output and miniature endplate potential (MEPP) frequency, again by activating PKA. 5. CGRP release was measured by radioimmunoassay. Release was increased by depolarization with elevated K+, but the amounts released appear to be below those needed to affect quantal size or output. Moreover, although elevated K+ can increase quantal size it acts by a pathway that does not involve PKA. We suggest that the most likely target of endogenously released CGRP is the regulation of circulation of the muscle.

Acetylcholine transport, storage, and release

ACh is released from cholinergic nerve terminals under both resting and stimulated conditions. Stimulated release is mediated by exocytosis of synaptic vesicle contents. The structure and function of cholinergic vesicles are becoming known. The concentration of ACh in vesicles is about 100-fold greater than the concentration in the cytoplasm. The AChT exhibits the lowest binding specificity among known ACh-binding proteins. It is driven by efflux of protons pumped into the vesicle by the V-type ATPase. A potent pharmacology of the AChT based on the allosteric VR has been developed. It has promise for clinical applications that include in vivo evaluation of the density of cholinergic innervation in organs based on PET and SPECT. The microscopic kinetics model that has been developed and the very low transport specificity of the vesicular AChT-VR suggest that the transporter has a channel-like or multidrug resistance protein-like structure. The AChT-VR has been shown to be tightly associated with proteoglycan, which is an unexpected macromolecular relationship. Vesamicol and its analogs block evoked release of ACh from cholinergic nerve terminals after a lag period that depends on the rate of release. Recycling quanta of ACh that are sensitive to vesamicol have been identified electrophysiologically, and they constitute a functional correlate of the biochemically identified VP2 synaptic vesicles. The concept of transmitter mobilization, including the observation that the most recently synthesized ACh is the first to be released, has been greatly clarified because of the availability of vesamicol. Differences among different cholinergic nerve terminal types in the sensitivity to vesamicol, the relative amounts of readily and less releasable ACh, and other aspects of the intracellular metabolism of ACh probably are more apparent than real. They easily could arise from differences in the relative rates of competing or sequential steps in the complicated intraterminal metabolism of ACh rather than from fundamental differences among the terminals. Nonquantal release of ACh from motor nerve terminals arises at least in part from the movement of cytoplasmic ACh through the AChT located in the cytoplasmic membrane, and it is blocked by vesamicol. Possibly, the proteoglycan component of the AChT-VR produces long-term residence of the macromolecular complex in the cytoplasmic membrane through interaction with the synaptic matrix. The preponderance of evidence suggests that a significant fraction of what previously, heretofore, had been considered to be nonquantal release from the motor neuron actually is quantal release from the neuron at sites not detected electrophysiologically.(ABSTRACT TRUNCATED AT 400 WORDS)

Down-regulation of quantal size at frog neuromuscular junctions: possible roles for elevated intracellular calcium and for protein kinase C

Previous work showed that quantal size can be at least doubled at the frog neuromuscular junction by pretreatment with hormones or hypertonic solutions, primarily by the release of more acetylcholine (ACh) per quantum. Once increased, quantal size slowly declined over hours. Quantal size was measured from miniature end-plate potentials (MEPPs) or currents (MEPCs). In the present experiments, preparations in which quantal size had been increased were exposed to 17-25 mM [K+], quantal size decreased within minutes. Release of comparable numbers of quanta by nerve stimulation did not decrease size. K(+)-solutions did not decrease size if Ca2+ was omitted or replaced with Sr2+. The phosphokinase C (PKC) activators phorbol 12,13-diacetate (PDA) and 1-oleoyl-2-acetyl-rac-glycerol (OAG) also decreased quantal size within minutes when applied in a hypertonic solution that increased the rate of spontaneous release. Phorbol 12,13-dideconate, which does not activate PKC, did not decrease quantal size. The size decrease triggered by K(+)-solutions or PKC activators was blocked by 100 microM 1-(5-isoquinolinyl-sulfonyl)-2-methyl-piperazine (H7), a protein kinase inhibitor. Apparently, increasing [K+] elevated intracellular [Ca2+], which activates PKC, and which leads to the down-regulation of quantal size. During the period in which size is decreasing, there appears to be large and normal subpopulations of MEPP sizes, with normal gradually replacing large. This suggests that large quanta are formed by adding additional ACh to preformed quanta shortly before they are available for release.

The regulation of quantal size

Quantal size can be altered experimentally by numerous treatments that seem to lack any common thread. The observations may seem haphazard and senseless unless clear distinctions are made from the outset. Some treatments shift the size of the entire population of quanta. These quanta are released by nerve stimulation. Other treatments add quanta of abnormal size or shape--monstrosities--to the population (4.0). Usually, perhaps even invariably, the monstrosities are not released by nerve stimulation. 6.1. POPULATION SIZE INCREASES. 6.1.1. Quantal size must be regulated. The size of the entire quantal population can be experimentally shifted to a larger size, with the mean rising two- or even four-fold. Before these observations, it was reasonable to suppose that quantal size was relatively fixed, with little room for maneuver. A logical picture is that synaptic vesicles have a maximum transmitter capacity, and usually they are filled to the brim. This picture is wrong. The quantity of transmitter packaged in the quantum must be regulated by the neuron, so depending on circumstances, quantal size can be increased or decreased. Figure 18 makes the case for regulation more strongly than words. We are beginning to identify some of the signals for up and down regulation, and the first steps have been made in discovering the signal transduction pathways, but we are far from a true understanding. This is hardly surprising, because our information about how transmitter molecules are assembled into quantal packages is still imperfect. Until we understand the engine, it may be difficult to picture the accelerator or the brake. 6.1.2. Signals that up regulate size. Stimulation of the presynaptic neuron increases quantal size at the NMJ, at synapses in autonomic ganglia and in hippocampus. The stimulus parameters necessary to elicit the quantal size increase have not been explored sufficiently in any of these cases, and all deserve further investigation. At both frog and mouse NMJs quantal size is roughly doubled following exposure to hypertonic solutions, which elevate the rate of spontaneous quantal release. This discovery, coupled with the increases caused by tetanic stimulation, suggested that the signal for up regulation is a period of greatly enhanced quantal output. The size increase takes about 15 min in hypertonic solution in mouse and about 60 min in frog. Highly hypertonic solutions do not increase the rate of quantal release in frog; they also do not increase quantal size. This supported the idea that quantal release rate is the signal for up regulation.(ABSTRACT TRUNCATED AT 400 WORDS)

Non-quantal acetylcholine release at mouse neuromuscular junction: effects of elevated quantal release and aconitine

The rate of non-quantal acetylcholine (ACh) release was estimated at the mouse neuromuscular junction by observing the effect of (+)-tubocurarine on endplate membrane potential or current in preparations pretreated with an irreversible anti-acetylcholinesterase (anti-AChE). Voltage clamping was an effective method for measuring non-quantal release. Non-quantal release was markedly inhibited by 10 microM aconitine. Non-quantal release was not significantly increased by 10 microM dihyroouabain (DHO). (It has been reported that ouabain increases the leak). Non-quantal release was roughly doubled following exposure to hypertonic solution or to elevated K(+)-solution. This is in accord with the hypothesis that the leak is by way of ACh transporters incorporated into the terminal membrane following exocytosis, but other interpretations remain to be tested.